Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigt

Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigt
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR

Zweites Quartal

/by
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed

Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

Second quarter

/by
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
arcticnovartis

  • Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 
  • Clinically meaningful improvements of protein in urine observed as early as two weeks, with sustained reduction over treatment period1
  • Fabhalta targets the alternative complement pathway; activation is a key driver of inflammation associated with IgAN2-4
/by
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
arcticnovartis

  • Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 
  • Clinically meaningful improvements of protein in urine observed as early as two weeks, with sustained reduction over treatment period1
  • Fabhalta targets the alternative complement pathway; activation is a key driver of inflammation associated with IgAN2-4
/by
Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next

Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next
weberfr8

/by
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
arcticnovartis

  • Adds potential first-in-class, N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads
  • Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact across multiple solid tumor settings
/by
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
arcticnovartis

  • First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults
     
  • Fixed, one-time dose designed to replace the faulty SMN1 gene, providing a distinct option from ongoing dosing approaches
/by
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
arcticnovartis

  • Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile and no observed liver safety concerns2

  • With global CIndU prevalence of 29 million3,4; greater than 50% of patients experience significant disease burden despite treatment with H1-antihistamines; no approved targeted therapies exist5,6
/by
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
arcticnovartis

  • Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentation
  • New Phase IIIb REMIXED extension data in chronic spontaneous urticaria to provide additional efficacy and safety data for Rhapsido
  • Phase II Rhapsido food allergy dose-response analysis in adults with IgE-mediated peanut allergy also to be presented

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of A

/by